drugset / Trial / NCT04237740
Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy and safety of lenvatinib in the treatment of recurrence of hepatocellular carcinoma after liver transplantation.
Timeline
- Start
- 2020-05-01
- Primary completion
- 2022-01-01
- Completion
- 2022-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | — |
| Subject | Lenvatinib | Small molecule | 12 mg | — |